

20 March 2026
Medclair AB (publ)

Notice of Annual General Meeting in Medclair AB (publ)

The shareholders of Medclair AB (publ), reg. no. 556691–3728 (the “Company”), are hereby invited to attend the Annual General Meeting on Wednesday, 22 April 2026 at 13:00 CET, at the Company’s premises at Fraktflygargatan 1, Skarpnäck, Sweden.

Notification and right to participate

Shareholders who wish to participate in the Annual General Meeting must:

- be registered in the share register maintained by Euroclear Sweden AB on 14 April 2026, and
- notify the Company of their intention to attend no later than 20 April 2026

Notification of attendance shall be made via email to info@medclair.com.

The notification shall include name, personal or corporate identity number, and shareholding.

Nominee-registered shares

Shareholders whose shares are nominee-registered must, in order to be entitled to participate in the meeting, request that the shares be temporarily registered in their own name in the share register as of Tuesday, 14 April 2026. Such registration (so-called voting rights registration) must be requested from the nominee in accordance with the nominee’s procedures in sufficient time in advance as determined by the nominee. Voting rights registrations completed no later than the second banking day after 14 April 2026 will be taken into account when preparing the share register.

Proxy

Shareholders represented by proxy and representatives of legal entities are requested to submit a written, signed and dated power of attorney in original, together with a certificate of registration or other authorization documents, to the Company well in advance of the Annual General Meeting. The power of attorney and certificate of registration may not be older than one year at the date of the meeting, unless the power of attorney specifies a longer period of validity, which may not exceed five years. A proxy form is available on the Company’s website:

<https://www.medclair.com/investor-relations>

Majority requirements

A valid resolution under item 13 requires approval by shareholders representing at least two-thirds of both the votes cast and the shares represented at the meeting.

20 March 2026
Medclair AB (publ)

Financial statements and proposals

The annual report, auditor's report, and complete proposals will be available on the Company's website: <https://www.medclair.com/investor-relations> no later than three weeks prior to the meeting and will be sent to shareholders who request it and provide their email address.

Proposed agenda

1. Opening of the meeting and election of Chairman of the meeting
2. Preparation and approval of the voting list
3. Election of person to keep the minutes
4. Election of one or two persons to verify the minutes
5. Determination of whether the meeting has been duly convened
6. Approval of the agenda
7. Presentation of the annual report and auditor's report, as well as the consolidated financial statements and auditor's report for the group
8. Resolutions regarding:
 - a. adoption of the income statement and balance sheet, as well as the consolidated income statement and consolidated balance sheet
 - b. allocation of the Company's profit or loss in accordance with the adopted balance sheet
 - c. discharge from liability for the Board members and the CEO
9. Resolution on Board and auditor remuneration
10. Election of Board members and deputy Board members
11. Election of auditor
12. Election of nomination committee
13. Resolution on authorization for the Board to resolve on new issues
14. Closing of the meeting

Proposals for resolutions

Items 9–11 – Board and auditor remuneration, election of Board members and deputy Board members, and election of auditor

The Nomination Committee's proposals will be presented on the Company's website one week prior to the Annual General Meeting.

Item 12 – Election of nomination committee

It is proposed that the Nomination Committee for the Annual General Meeting 2027 shall consist of the three largest shareholders in terms of voting power as of 31 December 2026, together with the Chairman of the Board.

20 March 2026
Medclair AB (publ)

Item 13 – Authorization for the Board to resolve on new issues

The Board proposes that the Annual General Meeting resolves to authorize the Board, during the period until the next Annual General Meeting, on one or more occasions and with or without deviation from the shareholders' preferential rights, to resolve on the issue of new shares, convertible bonds and/or warrants.

Payment may be made in cash, in kind, by set-off or otherwise be subject to conditions.

The Company's share capital and number of shares may, by virtue of the authorization, be increased in total up to the limits set out in the Articles of Association.

Deviation from the shareholders' preferential rights shall be possible in order to strengthen the Company's financial position and to enable acquisitions of companies or businesses. The issue price shall, in the event of deviation from the shareholders' preferential rights and in the case of payment in kind or by set-off, correspond to the market value of the share, subject to any market-based issue discount.

Personal data

Personal data obtained from notifications of attendance at the meeting, as well as information about representatives, proxies and assistants, will be used solely for registration, preparation of the voting list for the meeting and, where applicable, the minutes of the meeting.

Stockholm, March 2026
Medclair AB (publ)
The Board of Directors

Contacts

For further information, please contact:

Jonas Lundh, Medclair AB (publ), Phone: +46 76 193 90 90, Email: jonas.lundh@medclair.com

About Us

Medclair is a Swedish cleantech company and a leader in safe and sustainable nitrous oxide management. With operations in twenty countries, Medclair provides innovative solutions that significantly reduce the climate impact of nitrous oxide while improving workplace safety.

The company is listed on NGM Nordic SME. For more information, please visit www.medclair.com.